Drug Type Small molecule drug |
Synonyms BMS 986141, UDM-003183 |
Target |
Mechanism PAR-4 antagonists(Protease-activated receptor-4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H23N5O5S2 |
InChIKeyKEEBLYWBELVGPQ-UHFFFAOYSA-N |
CAS Registry1478711-48-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Coronary Artery Disease | Phase 2 | GB | 25 Mar 2022 | |
Acute Ischemic Stroke | Phase 2 | US | 25 Apr 2016 | |
Acute Ischemic Stroke | Phase 2 | JP | 25 Apr 2016 | |
Brain Infarction | Phase 2 | US | 25 Apr 2016 | |
Brain Infarction | Phase 2 | JP | 25 Apr 2016 | |
Ischemic Attack, Transient | Phase 2 | US | 25 Apr 2016 | |
Ischemic Attack, Transient | Phase 2 | JP | 25 Apr 2016 | |
Thrombosis | Phase 2 | US | 25 Apr 2016 | |
Thrombosis | Phase 2 | JP | 25 Apr 2016 | |
Liver Diseases | Phase 1 | US | 11 Jan 2017 |
Phase 2 | 58 | (Arm 1: 90 mg Ticagrelor + 4 mg BMS-986141) | dtrfwyizyu(iqtfdwknzc) = svznjwjecp alxedvzton (xwqaxcmgtd, iwuwgohyge - guiasbqvgi) View more | - | 05 Dec 2023 | ||
(Arm 2: 75 mg Aspirin + 4 mg BMS-986141) | dtrfwyizyu(iqtfdwknzc) = rmssbhjqeb alxedvzton (xwqaxcmgtd, auegqgodbn - xtujqconxa) View more | ||||||
NCT02341638 (Pubmed) Manual | Phase 1 | - | 60 | vsxfvignex(xglvqibsvj) = fwjtvtqamq tobwhugwml (tgxidnrfej ) View more | Positive | 01 Dec 2023 | |
vsxfvignex(xglvqibsvj) = zwyheibxmv tobwhugwml (tgxidnrfej ) View more | |||||||
Not Applicable | - | - | woepvnccfk(jcppsrjaah) = xlfxvqdwya zkrnfgnjyu (rdhzbkrxqh ) View more | - | 01 Sep 2020 | ||
woepvnccfk(jcppsrjaah) = hpsirhulnv zkrnfgnjyu (rdhzbkrxqh ) View more | |||||||
Phase 2 | 16 | placebo+Aspirin | aagslmxlqh(ltdcwzqgbk) = sadsjqkbxz wecaijkdej (qlxdzzqahb, hqwhxbrdbz - avjsadugis) View more | - | 12 Jun 2018 |